Raw_name,h_score,h_gene,l_score,l_gene,h_seq,l_seq
AntiCD28,62.54,vh,62.76797,vk,EVKLQQSGPGLVTPSQSLSITCTVSGFSLSDYGVHWVRQSPGQGLEWLGVIWAGGGTNYNSALMSRKSISKDNSKSQVFLKMNSLQADDTAVYYCARDKGYSYYYSMDYWGQGTSVTVSS,DIETLQSPASLAVSLGQRATISCRASESVEYYVTSLMQWYQQKPGQPPKLLIFAASNVESGVPARFSGSGSGTNFSLNIHPVDEDDVAMYFCQQSRKYVPYTFGGGTKLEIK
Campath,68.38847,vh,67.61687,vk,EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGVMVTVSS,DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGTGTKLELK
Bevacizumab,67.92687,vh,75.70097,vk,EIQLVQSGPELKQPGETVRISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGEPTYAADFKRRFTFSLETSASTAYLQISNLKNDDTATYFCAKYPHYYGSSHWYFDVWGAGTTVTVSS,DIQMTQTTSSLSASLGDRVIISCSASQDISNYLNWYQQKPDGTVKVLIYFTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSTVPWTFGGGTKLEIK
Herceptin,61.70837,vh,73.41127,vk,QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGNRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK
Omalizumab,66.1576,vh,67.74777,vk,DVQLQESGPGLVKPSQSLSLACSVTGYSITSGYSWNWIRQFPGNKLEWMGSITYDGSSNYNPSLKNRISVTRDTSQNQFFLKLNSATAEDTATYYCARGSHYFGHWHFAVWGAGTTVTVSS,DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPILLIYAASYLGSEIPARFSGSGSGTDFTLNIHPVEEEDAATFYCQQSHEDPYTFGAGTKLEIK
Eculizumab,60.77877,vh,67.61687,vk,QVQLQQSGAELMKPGASVKMSCKATGYIFSNYWIQWIKQRPGHGLEWIGEILPGSGSTEYTENFKDKAAFTADTSSNTAYMQLSSLTSEDSAVYYCARYFFGSSPNWYFDVWGAGTTVTVSS,DIQMTQSPASLSASVGETVTITCGASENIYGALNWYQRKQGKSPQLLIYGATNLADGMSSRFSGSGSGRQYYLKISSLHPDDVATYYCQNVLNTPLTFGAGTKLELK
Tocilizumab,70.63037,vh,74.29917,vk,DVQLQESGPVLVKPSQSLSLTCTVTGYSITSDHAWSWIRQFPGNKLEWMGYISYSGITTYNPSLKSRISITRDTSKNQFFLQLNSVTTGDTSTYYCARSLARTTAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISSYLNWYQQKPDGTIKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTINNLEQEDIATYFCQQGNTLPYTFGGGTKLEIN
Pembrolizumab,66.33337,vh,66.26137,vk,QVQLQQPGAELVKPGTSVKLSCKASGYTFTNYYMYWVKQRPGQGLEWIGGINPSNGGTNFNEKFKNKATLTVDSSSSTTYMQLSSLTSEDSAVYYCTRRDYRFDMGFDYWGQGTTLTVSS,DIVLTQSPASLAVSLGQRAAISCRASKGVSTSGYSYLHWYQQKPGQSPKLLIYLASYLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRDLPLTFGTGTKLELK
Pertuzumab,70.63037,vh,71.35517,vk,EVQLQQSGPELVKPGTSVKISCKASGFTFTDYTMDWVKQSHGKSLEWIGDVNPNSGGSIYNQRFKGKASLTVDRSSRIVYMELRSLTFEDTAVYYCARNLGPSFYFDYWGQGTTLTVSS,DTVMTQSHKIMSTSVGDRVSITCKASQDVSIGVAWYQQRPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQYYIYPYTFGGGTKLEIK
Ixekizumab,60.16817,vh,80.22327,vk,QVQLQQSRPELVKPGASVKISCKASGYSFTDYNMNWVKQSNGKSLEWIGVINPNYGTTDYNQRFKGKATLTVDQSSRTAYMQLNSLTSEDSAVYYCVIYDYATGTGGYWGQGSPLTVSS,DVVLTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPFTFGSGTKLEIK
Palivizumab,67.755,vh,62.57017,vk,QVELQESGPGILQPSQTLSLTCSFSGFSLSTSGMSVGWIRQPSGEGLEWLADIWWDDKKDYNPSLKSRLTISKDTSSNQVFLKITGVDTADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQLTQSPAIMSASPGEKVTMTCSASSSVGYMHWYQQKSSTSPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSIQAEDVATYYCFQGSGYPFTFGQGTKLEIK
Certolizumab,68.94077,vh,70.18697,vk,QIQLVQSGPELKKPGETVKISCKASGYVFTDYGMNWVKQAPGKAFKWMGWINTYIGEPIYVDDFKGRFAFSLETSASTAFLQINNLKNEDTATYFCARGYRSYAMDYWGQGTSVTVSS,DIVMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASFLYSGVPYRFTGSGSGTDFTLTISTVQSEDLAEYFCQQYNIYPLTFGAGTKLELK
Idarucizumab,58.11487,vh,79.10717,vk,QVQLEQSGPGLVAPSQRLSITCTVSGFSLTSYIVDWVRQSPGKGLEWLGVIWAGGSTGYNSALRSRLSITKSNSKSQVFLQMNSLQTDDTAIYYCASAAYYSYYNYDGFAYWGQGTLVTVSA,DVVMTQTPLTLSVTIGQPASISCKSSQSLLYTNGKTYLYWLLQRPGQSPKRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCLQSTHFPHTFGGGTKLEIK
Reslizumab,62.88797,vh,69.81317,vk,EVKLLESGGGLVQPSQTLSLTCTVSGLSLTSNSVNWIRQPPGKGLEWMGLIWSNGDTDYNSAIKSRLSISRDTSKSQVFLKMNSLQSEDTAMYFCAREYYGYFDYWGQGVMVTVSS,DIQMTQSPASLSASLGETISIECLASEGISSYLAWYQQKPGKSPQLLIYGANSLQTGVPSRFSGSGSATQYSLKISSMQPEDEGDYFCQQSYKFPNTFGAGTKLELK
Solanezumab,70.38467,vh,80.35717,vk,EVKLVESGGGLVQPGGSLKLSCAVSGFTFSRYSMSWVRQTPEKRLELVAQINSVGNSTYYPDTVKGRFTISRDNAEYTLSLQMSGLRSDDTATYYCASGDYWGQGTTLTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLIYSDGNAYLHWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVETEDLGVYFCSQSTHVPWTFGGGTKLEIK
Lorvotuzumab,78.34757,vh,79.28577,vk,DVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGMHWVRQAPEKGLEWVAYISSGSFTIYHADTVKGRFTISRDNPKNTLFLQMTSLRAEDTAHYYCARMRKGYAMDYWGQGTTVTVSS,DVLMTQTPLSLPVSLGDQASISCRSSQIIIHSDGNTYLEWFLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLMISRVEAEDLGVYYCFQGSHVPHTFGGGTKLEIK
Pinatuzumab,63.66677,vh,80.17867,vk,QVQLQQSGPELVKPGASVKISCKASGYEFSRSWMNWVKQRPGQGREWIGRIYPGDGDTNYSGKFKGKATLTADKSSSTAYMQLSSLTSVDSAVYFCARDGSSWDWYFDVWGAGTTVTVSS,DILMTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTFLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSQFPYTFGGGTKVEIK
Etaracizumab,76.32487,vh,66.68227,vk,EVQLEESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQIPEKRLEWVAKVSSGGGSTYYLDTVQGRFTISRDNAKNTLYLQMSSLNSEDTAMYYCARHNYGSFAYWGQGTLVTVSA,ELVMTQTPATLSVTPGDSVSLSCRASQSISNHLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSNSWPHTFGGGTKLEIK
Talacotuzumab,64.755,vh,79.24787,vk,EVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMKWVKQSHGKSLEWIGDIIPSNGATFYNQKFKGKATLTVDRSSSTAYMHLNSLTSEDSAVYYCTRSHLLRASWFAYWGQGTLVTVSA,DFVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYLQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPYTFGGGTKLEIK
Rovalpituzumab,71.05937,vh,67.38327,vk,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMAWINTYTGEPTYADDFKGRFAFSLETSASTASLQIINLKNEDTATYFCARIGDSSPSDYWGQGTTLTVSS,SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVVWYQQKPGQSPKLLIYYASNRYTGVPDRFAGSGYGTDFSFTISTVQAEDLAVYFCQQDYTSPWTFGGGTKLEIR
Clazakizumab,56.54,vh,64.18187,vk,QSLEESGGRLVTPGTPLTLTCTASGFSLSNYYVTWVRQAPGKGLEWIGIIYGSDETAYATWAIGRFTISKTSTTVDLKMTSLTAADTATYFCARDDSSDWDAKFNLWGQGTLVTVSS,AYDMTQTPASVSAAVGGTVTIKCQASQSINNELSWYQQKPGQRPKLLIYRASTLASGVSSRFKGSGSGTEFTLTISDLECADAATYYCQQGYSLRNIDNAFGGGTEVVVK
Ligelizumab,59.91877,vh,66.30847,vk,QVQLQQSGAELMKPGASVKISCKTTGYTFSMYWLEWVKQRPGHGLEWVGEISPGTFTTNYNEKFKAKATFTADTSSNTAYLQLSGLTSEDSAVYFCARFSHFSGSNYDYFDYWGQGTSLTVSS,DILLTQSPAILSVSPGERVSFSCRASQSIGTNIHWYQQRTDGSPRLLIKYASESISGIPSRFSGSGSGTEFTLNINSVESEDIADYYCQQSDSWPTTFGGGTKLEIK
Crizanlizumab,65.40987,vh,69.9556,vk,QVQLQQSGPELVKPGALVKISCKASGYTFTSYDINWVKQRPGQGLEWIGWIYPGDGSIKYNEKFKGKATLTVDKSSSTAYMQVSSLTSENSAVYFCARRGEYGNYEGAMDYWGQGTTVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGHSYMNWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSDENPLTFGTGTKLELK
Mogamulizumab,70.58827,vh,75.6256,vk,EVQLVESGGDLMKPGGSLKISCAASGFIFSNYGMSWVRQTPDMRLEWVATISSASTYSYYPDSVKGRFTISRDNAENSLYLQMNSLRSEDTGIYYCGRHSDGNFAFGYWGRGTLVTVSA,DVLMTQTPLSLPVSLGDQASISCRSSRNIVHINGDTYLEWYLQRPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSLLPWTFGGGTRLEIR
Refanezumab,70.83337,vh,78.23017,vk,EIQLVQSGPELKKPGETNKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFTGRFAFSLETSASTAYLQISNLKNEDTATYFCARNPINYYGINYEGYVMDYWGQGTLVTVSS,NIMMTQSPSSLAVSAGEKVTMSCKSSHSVLYSSNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTIINVHTEDLAVYYCHQYLSSLTFGTGTKLEIK
